Global

The European Commission approved sacituzumab govitecan plus pembrolizumab for treatment-naive, PD-L1-positive metastatic triple-negative breast cancer.

The NMPA accepted the NDA for the PD-L1/4-1BB–directed bispecific antibody opamtistomig in previously treated advanced extrapulmonary NEC.

The European Commission approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior therapy, offering the regimen as early as second line.

T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.

Natera has submitted Signatera to Japan's PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer.

Dato-DXd was approved in the European Union as monotherapy for patients with first-line metastatic TNBC who are not candidates for immunotherapy.

Amol Akhade, MD, discusses how biosimilars, subcutaneous formulations, and dose optimization each bear on the cost of cancer care.

Amol Akhade, MD, discusses the pharmacologic rationale for reduced-dose checkpoint inhibition and the funding barrier to definitive randomized evidence.

Amol Akhade, MD, discusses how cost shapes immunotherapy decisions and what standard cost-effectiveness measures miss for individual patients.

The CHMP recommended EU approval of T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer,

The CHMP has recommended the approval of sacituzumab govitecan/pembrolizumab for treatment-naive, PD-L1-positive metastatic TNBC in the European Union.

Camizestrant plus a CDK4/6 inhibitor was approved in the European Union for ER-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.

Johannes Schetelig, MD, MSc, discusses data for anti–T-lymphocyte globulin vs post-transplant cyclophosphamide for GVHD prophylaxis in hematologic malignancies.

An updated HARMONi analysis showed a consistent OS benefit with ivonescimab plus chemotherapy in EGFR-mutated NSCLC.

Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.

Iza-bren was approved in China for recurrent or metastatic ESCC following progression on platinum-based chemotherapy and PD-1/PD-L1 inhibition.

Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.

Catch up on insights into the global development of breast cancer treatments in the global spotlight.

The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.

Ruxolitinib plus extracorporeal photopheresis drove responses in steroid-refractory or -dependent chronic graft-vs-host disease.

The European Commission has approved epcoritamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma.

Savolitinib received conditional NMPA approval in China for MET-amplified gastric or GEJ adenocarcinoma after prior systemic therapy, based on a 32.3% ORR.

Ropeginterferon alfa-2b has been approved by Health Canada for the treatment of adult patients with polycythemia vera.

The European Union has approved trastuzumab deruxtecan for patients with previously treated, HER2-positive metastatic solid tumors.

CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.

CHMP backs teclistamab plus daratumumab for earlier use in relapsed/refractory multiple myeloma following strong MajesTEC-3 results.

The CHMP has recommended datopotamab deruxtecan for patients with first-line metastatic TNBC who are not candidates for immunotherapy.

Daratumumab-based retreatment remained active in a broadly inclusive, transplant-ineligible newly diagnosed multiple myeloma population.

Izalontamab brengitecan has been approved in China for recurrent/metastatic NPC following disease progression on chemotherapy and PD-1/PD-L1 inhibition.

The European Commission approved perioperative pembrolizumab plus enfortumab vedotin for patients with cisplatin-ineligible resectable MIBC.